

Form PTO-1449 (modified)		Atty. Docket No.: DFCL:006US	Serial No.: 10/598,295
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)			
U.S. Patent Documents <i>See Page 1-2</i>		Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 3-19</i>

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1	10/553,028	10/11/05	Belmares <i>et al.</i>	514	018	10/11/05
	A2	2002/0110841	08/15/02	Kufe	435	7.23	12/26/01
	A3	2003/0148969	08/07/03	Dobie <i>et al.</i>	514	44	12/20/01
	A4	2004/0018181	01/29/04	Kufe <i>et al.</i>	424	93.21	05/29/03
	A5	2004/0166543	08/26/04	Kufe	435	7.23	12/11/03
	A6	2004/0209832	10/21/04	McSwiggen	514	44	09/23/03
	A7	2005/0042209	02/24/05	Kufe <i>et al.</i>	424	93.21	02/13/04
	A8	2005/0053606	03/10/05	Kufe <i>et al.</i>	424	155.1	09/11/01
	A9	5,506,343	04/09/96	Kufe	530	387.7	10/25/94
	A10	5,530,101	06/25/96	Queen <i>et al.</i>	530	387.3	12/19/90
	A11	5,612,895	03/18/97	Balaji <i>et al.</i>	702	19	04/21/95
	A12	5,766,833	06/16/98	Balance <i>et al.</i>	435	69.7	11/17/93
	A13	5,776,427	07/07/98	Thorpe <i>et al.</i>	424	1.49	06/01/95
	A14	5,801,154	09/01/98	Baracchini <i>et al.</i>	514	44	04/08/97
	A15	5,861,381	01/19/99	Chambon <i>et al.</i>	514	44	06/07/95
	A16	5,998,148	12/07/99	Bennett <i>et al.</i>	435	6	04/08/99
	A17	6,020,363	02/01/00	Hirano <i>et al.</i>	514	456	12/17/98
	A18	6,054,438	04/25/00	Taylor-Papadimitriou <i>et al.</i>	514	44	06/01/95
	A19	6,074,841	06/13/00	Gearing <i>et al.</i>	435	69.1	11/19/96
	A20	6,222,020	04/24/01	Taylor-Papadimitriou <i>et al.</i>	530	395	06/01/95
	A21	6,589,921	07/08/03	Herrmann <i>et al.</i>	514	456	02/27/01
	A22	6,716,627	04/06/04	Dobie	435	375	12/20/01

25794698.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No.: DFCL:006US	Serial No.: 10/598,295
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)			
U.S. Patent Documents <i>See Page 1-2</i>		Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 3-19</i>

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A23	60/308,307	07/27/01	Kufe			07/27/01
	A24	60/502,111	09/11/03	Jecminek <i>et al.</i>			09/11/03

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language
	B1	EP 1103623	07/01/98	Europe	English
	B2	WO 00/25827	05/11/00	WIPO	English
	B3	WO 00/34468	06/15/00	WIPO	English
	B4	WO 00/77031	12/21/00	WIPO	English
	B5	WO 01/12217	02/22/01	WIPO	English
	B6	WO 01/18035	03/15/01	WIPO	English
	B7	WO 01/57068	08/09/01	WIPO	English
	B8	WO 02/058450	08/01/02	WIPO	English
	B9	WO 02/22685	03/21/02	WIPO	English
	B10	WO 02/31512	04/18/02	WIPO	English
	B11	WO 03/014303	02/20/03	WIPO	English
	B12	WO 03/088995	10/30/03	WIPO	English
	B13	WO 2004/044160	05/27/04	WIPO	English
	B14	WO 2004/092339	10/28/04	WIPO	English
	B15	WO 93/20841	10/28/93	WIPO	English
	B16	WO 96/03502	02/08/96	WIPO	English

25794698.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No.:	Serial No.:
		DFCL:006US	10/598,295
List of Patents and Publications for Applicant's			
INFORMATION DISCLOSURE STATEMENT			
(Use several sheets if necessary)			
U.S. Patent Documents <i>See Page 1-2</i>		Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 3-19</i>

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Adams and Cory, "The Bcl-2 Protein Family: Arbiters of Cell Survival," <i>Science</i> , 281:1322-1326, 1998.
	C2	Agrawal and Kandimalla, "Antisense therapeutics: is it as simple as complementary base recognition?" <i>Molecular Medicine Today</i> , 6:72-81, 2000.
	C3	Akagi <i>et al.</i> , "CA19-9 epitope a possible marker for MUC-1/Y protein," <i>Int. J. Oncol.</i> , 18:1085-1091, 2001.
	C4	Ashkenazi and Dixit, "Apoptosis control by death and decoy receptors," <i>Curr. Opin. Cell Biol.</i> , 11:255-260, 1999.
	C5	Ashkenazi and Dixit, "Death Receptors: Signaling and Modulation," <i>Science</i> , 281:1305-1308, 1998.
	C6	Ashkenazi <i>et al.</i> , "Safety and antitumor activity of recombinant soluble Apo2 ligand," <i>J. Clin. Invest.</i> , 104:155-162, 1999.
	C7	Backstrom <i>et al.</i> , "Recombinant MUC1 mucin with a breast cancer-like O-glycosylation produced in large amounts in Chinese-hamster ovary cells," <i>Biochemical Journal</i> , 376:677-686, 2003.
	C8	Banerjee, "Omega amino acids in peptide design: incorporation into helices," <i>Biopolymers</i> , 39:769-77, 1996.
	C9	Barry and Sharkey, "Observer reproducibility during computer-assisted planimetric measurements of nuclear features," <i>Hum. Pathol.</i> , 16:225-7, 1985.
	C10	Barry <i>et al.</i> , "Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia," <i>Biochemical Pharmacology</i> , 40:2353-2362, 1990.
	C11	Baruch <i>et al.</i> , "Preferential expression of novel MUC1 tumor antigen isoforms in human epithelial tumors and their tumor-potentiating function," <i>Int. J. Cancer</i> , 71:741-749, 1997.
	C12	Baruch <i>et al.</i> , "The breast cancer-associated MUC1 gene generates both a receptor and its cognate binding protein," <i>Cancer Res.</i> , 59:1552-1561, 1999.
	C13	Batra <i>et al.</i> , "Transfection of the human MUC1 mucin gene into a poorly differentiated human pancreatic tumor cell line, Panc1: integration, expression and ultrastructural changes," <i>J. Cell Science</i> , 100:841-849, 1991.

25794698.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No.: DFCI:006US	Serial No.: 10/598,295
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT <small>(Use several sheets if necessary)</small>			
U.S. Patent Documents <i>See Page 1-2</i>		Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 3-19</i>

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C14	Bellgrau <i>et al.</i> , "A role for CD95 ligand in preventing graft rejection," <i>Nature</i> , 377:630-632, 1995.
	C15	Berger <i>et al.</i> , "Respiratory carcinoma cell lines: MUC genes and glycoconjugates," <i>American Journal of Respiratory Cell and Molecular Biology</i> , 20:500-510, 1999.
	C16	Bergeron <i>et al.</i> , "MAUB is a new mucin antigen associated with bladder cancer," <i>J. Biol. Chem.</i> , 271:6933-6940, 1996.
	C17	Beusen <i>et al.</i> , "Conformational mimicry: synthesis and solution conformation of a cyclic somatostatin hexapeptide containing a tetrazole cis amide bond surrogate," <i>Biopolymers</i> , 36:181-200, 1995.
	C18	Bird <i>et al.</i> , "Single-chain antigen-binding proteins," <i>Science</i> , 242:423-6, 1988.
	C19	Bitko <i>et al.</i> , "Inhibition of respiratory viruses by nasally administered siRNA," <i>Nature Med.</i> , 11:50-55, 2005.
	C20	Bodmer <i>et al.</i> , "Cysteine 230 is essential for the structure and activity of the cytotoxic ligand TRAIL," <i>J. Biol. Chem.</i> , 275:20632-20637, 2000.
	C21	Boldin <i>et al.</i> , "Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death," <i>Cell</i> , 85:803-815, 1996.
	C22	Brossart <i>et al.</i> , "Identification of HLA-A2-restricted T-cell epitopes derived from MUC1 tumor antigen for broadly applicable vaccine therapies," <i>Blood</i> , 93:4309-4317, 1999.
	C23	Brunner <i>et al.</i> , "pangolin encodes a Lef-1 homologue that acts downstream of Armadillo to transduce the Wingless signal in <i>Drosophila</i> ," <i>Nature</i> , 385:829-33, 1997.
	C24	Bumcrot <i>et al.</i> , "RNAi therapeutics: a potential new class of pharmaceutical drugs," <i>Nature Chemical Biology</i> , 2:711-719, 2006.
	C25	Bunz, "Cell death and cancer therapy," <i>Curr. Opin. Pharmacol.</i> , 1:337-341, 2001.
	C26	Burns and El-Deiry, "Identification of inhibitors of TRAIL-induced death (ITIDs) in the TRAIL-sensitive colon carcinoma cell line SW480 using a genetic approach," <i>J. Biol. Chem.</i> , 276:37879-37886, 2001.
	C27	Busfield <i>et al.</i> , "Characterization of a neuregulin-related gene, <i>Don-1</i> , that is highly expressed in restricted regions of the cerebellum and hippocampus," <i>Mol. Cell. Biol.</i> , 17:4007-4014, 1997.

25794698.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No.: DFCI:006US	Serial No.: 10/598,295
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 3-19</i>

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C28	Chang <i>et al.</i> , "Ligands for ErbB-family receptors encoded by a neuregulin-like gene," <i>Nature</i> , 387:509-512, 1997.
	C29	Chaudhary <i>et al.</i> , "A rapid method of cloning functional variable-region antibody genes in <i>Escherichia coli</i> as single-chain immunotoxins," <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 87:1066-70, 1990.
	C30	Ciborowski <i>et al.</i> , "Screening of anti-MUC1 antibodies for reactivity with native (ascites) and recombinant (baculovirus) MUC1 and for blocking MUC1 specific cytotoxic T-lymphocytes," <i>Tumor Biology</i> , 19:147-151, 1998.
	C31	Console <i>et al.</i> , "Antennapedia and HIV transactivator of transcription (TAT) "protein transduction domains" promote endocytosis of high molecular weight cargo upon binding to cell surface glycosaminoglycans," <i>J. Biol. Chem.</i> , 278:35109-14, 2003.
	C32	Creagan <i>et al.</i> , "Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma," <i>J. Clin. Oncol.</i> , 17:1884-1890, 1999.
	C33	Daniel and Reynolds, "The catenin p120(ctn) interacts with Kaiso, a novel BTB/POZ domain zinc finger transcription factor," <i>Mol. Cell. Biol.</i> , 19:3614-23, 1999.
	C34	Datta <i>et al.</i> , "Overexpression of Bcl-XL by cytotoxic drug exposure confers resistance to ionizing radiation-induced internucleosomal DNA fragmentation," <i>Cell Growth Differ.</i> , 6:363-370, 1995.
	C35	Dawson <i>et al.</i> , "Synthesis of proteins by native chemical ligation," <i>Science</i> , 266:776-779, 1994.
	C36	Deng <i>et al.</i> , "TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO," <i>Genes Dev.</i> , 16:33-45, 2002.
	C37	Derossi <i>et al.</i> , "Cell internalization of the third helix of the Antennapedia homeodomain is receptor-independent," <i>J. Biol. Chem.</i> , 271:18188-93, 1996.
	C38	Derossi <i>et al.</i> , "The third helix of the Antennapedia homeodomain translocates through biological membranes," <i>J. Biol. Chem.</i> , 269:10444-50, 1994.
	C39	Deveraux and Reed, "IAP family proteins—suppressors of apoptosis," <i>Genes Dev.</i> , 13:239-52, 1999.
	C40	Dillman, "Antibodies as cytotoxic therapy," <i>J. Clin. Oncology</i> , 12:1497-1515, 1994.

25794698.1

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No.: DFC1:006US	Serial No.: 10/598,295
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT <small>(Use several sheets if necessary)</small>			
U.S. Patent Documents <i>See Page 1-2</i>		Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 3-19</i>

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C41	Dorn <i>et al.</i> , "Down-regulation of the human tumor antigen mucin by gemcitabine on the pancreatic cancer cell line capan-2," <i>Anticancer Research</i> , 24:821-826, 2004.
	C42	Doyle, "Crystal structures of a complexed and peptide-free membrane protein-binding domain: molecular basis of peptide recognition by PDZ," <i>Cell</i> , 85:1067-76, 1996.
	C43	Drucker <i>et al.</i> , "Tamoxifen enhances apoptotic effect of cisplatin on primary endometrial cell cultures," <i>Anticancer Research</i> , 23:1549-1554, 2003.
	C44	Du <i>et al.</i> , "Smac, a Mitochondrial Protein that Promotes Cytochrome c-Dependent Caspase Activation by Eliminating IAP Inhibition," <i>Cell</i> , 102:33-42, 2000.
	C45	Dykxhoorn <i>et al.</i> , "The silent treatment: siRNAs as small molecule drugs," <i>Gene Therapy</i> , 13:541-552, 2006.
	C46	Elbashir <i>et al.</i> , "Analysis of gene function in somatic mammalian cells using small interfering RNAs," <i>Methods</i> , 26:199-213, 2002.
	C47	Elbashir <i>et al.</i> , "RNA interference is mediated by 21-and 22-nucleotide RNAs," <i>Genes and Development</i> , 15:188-200, 2001.
	C48	Elliot and O'Hare, "Intercellular trafficking and protein delivery by a herpesvirus structural protein," <i>Cell</i> , 88:223-33, 1997.
	C49	Elmquist <i>et al.</i> , "VE-cadherin-derived cell-penetrating peptide, pVEC, with carrier functions," <i>Exp. Cell Res.</i> , 269:237-44, 2001.
	C50	Emoto <i>et al.</i> , "Proteolytic activation of protein kinase C delta by an ICE-like protease in apoptotic cells," <i>EMBO J.</i> , 14:6148-6156, 1995.
	C51	Faivre <i>et al.</i> , "Supraadditive effect of 2',2'difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines," <i>Cancer Chemother. Pharmacol.</i> , 44:117-123, 1999.
	C52	Feigl, "2,8-Dimethyl-4-(carboxymethyl)-6-(aminomethyl)phenoxythiin S-Dioxide: An Organic Substitute for the beta-Turn in Peptides," <i>J. Amer. Chem. Soc.</i> , 108:181-2, 1986.
	C53	Finn <i>et al.</i> , "MUC-1 Epithelial Tumor Mucin-Based Immunity and Cancer Vaccines," <i>Immunol. Rev.</i> , 145:61-89, 1995.
	C54	Frankel and Pabo, "Cellular uptake of the tat protein from human immunodeficiency virus," <i>Cell</i> , 55:1189-93, 1989.

25794698.1

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No.:	Serial No.:
		DFCL:006US	10/598,295
List of Patents and Publications for Applicant's			
INFORMATION DISCLOSURE STATEMENT			
(Use several sheets if necessary)			
U.S. Patent Documents <i>See Page 1-2</i>		Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 3-19</i>

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C55	French and Tschopp, "Inhibition of Death Receptor Signaling by FLICE-inhibitory Protein as a Mechanism for Immune Escape of Tumors," <i>J. Exp. Med.</i> , 190:891-893, 1999.
	C56	Futaki <i>et al.</i> , "Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery," <i>J. Biol. Chem.</i> , 276:5836-40, 2001.
	C57	Geisbert <i>et al.</i> , "Postexposure Protection of Guinea Pigs against a Lethal Ebola Virus Challenge is Conferred by RNA Interference," <i>J. Infectious Diseases</i> , 193:1650-1657, 2006.
	C58	Gendler <i>et al.</i> , "A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats," <i>J. Biol. Chem.</i> , 263:12820-12823, 1988.
	C59	Gendler <i>et al.</i> , "Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin," <i>J. Biol. Chem.</i> , 265:15286-15293, 1990.
	C60	Gopalakrishnan <i>et al.</i> , "Application of Micro Arrayed Compound Screening (microARCS) to identify inhibitors of caspase-3," <i>J. Biomol. Screen</i> , 7:317-23, 2002.
	C61	Green and Loewenstein, "Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein," <i>Cell</i> , 55:1179-88, 1989.
	C62	Griffith <i>et al.</i> , "CD95-Induced Apoptosis of Lymphocytes in an Immune Privileged Site Induces Immunological Tolerance," <i>Immunity</i> , 5:7-16, 1996.
	C63	Gross <i>et al.</i> , "Caspase cleaved BID targets mitochondria and is required for cytochrome c release, while BCL-XL prevents this release but not tumor necrosis factor-R1/Fas death," <i>J. Biol. Chem.</i> , 274:1156-1163, 1999.
	C64	Grzelinski <i>et al.</i> , "RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts," <i>Human Gene Therapy</i> , 17:751-766, 2006.
	C65	Haim <i>et al.</i> , "Dexamethasone, cytarabine, ifosfamide, and cisplatin as salvage therapy in Non-Hodgkin lymphoma," <i>Am. J. Clin. Oncol.</i> , 22:47-50, 1999.
	C66	Hammond <i>et al.</i> , "Post-transcriptional gene silencing by double-stranded RNA," <i>Nature Genetics</i> , 2:110-119, 2001.
	C67	Hanson <i>et al.</i> , "MUC1 expression in primary breast cancer: the effect of tamoxifen treatment," <i>Breast Cancer Research and Treatment</i> , 67:215-222, 2001.

25794698.1

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No.: DFCI:006US	Serial No.: 10/598,295
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT <small>(Use several sheets if necessary)</small>		
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 3-19</i>

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C68	Harborth <i>et al.</i> , "Identification of essential genes in cultured mammalian cells using small interfering RNAs," <i>J. Cell Science</i> , 114:4557-4565, 2001.
	C69	Harrison, "Peptide-surface association: the case of PDZ and PTB domains," <i>Cell</i> , 86:341-343, 1996.
	C70	Hartman <i>et al.</i> , "MUC1 isoform specific monoclonal antibody 6E6/2 detects preferential expression of the novel MUC1/Y protein in breast and ovarian cancer," <i>Int. J. Cancer</i> , 82:256-267, 1999.
	C71	Herr and Debatin, "Cellular stress response and apoptosis in cancer therapy," <i>Blood</i> , 98:2603-2614, 2001.
	C72	Higashiyama <i>et al.</i> , "A novel brain-derived member of the epidermal growth factor family that interacts with ErbB3 and ErbB4," <i>J. Biochem.</i> , 122:675-680, 1997.
	C73	Higgins, "Comparison of the solution conformations of a human immunodeficiency virus peptidomimetic and its retro-inverso isomer using 1H NMR spectroscopy," <i>J. Pept. Res.</i> , 50:421-35, 1997.
	C74	Hird <i>et al.</i> , "Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody," <i>Br. J. Cancer</i> , 68:403-406, 1993.
	C75	Hruby <i>et al.</i> , "Design of peptides, proteins, and peptidomimetics in chi space," <i>Biopolymers</i> , 43:219-66, 1997.
	C76	Hunt and Evans, "Till Death Us Do Part," <i>Science</i> , 293:1784-1785, 2001.
	C77	Huston <i>et al.</i> , "Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in <i>Escherichia coli</i> ," <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 85:5879-83, 1988.
	C78	Hymowitz <i>et al.</i> , "Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5," <i>Mol. Cell.</i> , 4:563-571, 1999.
	C79	Ikeda <i>et al.</i> , "Induction of redox imbalance and apoptosis in multiple myeloma cells by the novel triterpenoid 2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid," <i>Molecular Cancer Therapeutics</i> , 3:39-45, 2004.
	C80	Irmler <i>et al.</i> , "Inhibition of death receptor signals by cellular FLIP," <i>Nature</i> , 388:190-195, 1997.

25794698.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No.: DFCI:006US	Serial No.: 10/598,295
List of Patents and Publications for Applicant's		Applicant: Donald W. KUFE Surender KHARBANDA	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Filing Date: April 5, 2007	Group: 1635
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 3-19</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C81	Itzkowitz <i>et al.</i> , "Sialosyl-Tn. A novel mucin antigen associated with prognosis in colorectal cancer patients," <i>Cancer</i> , 66:1960-6, 1990.
	C82	Jaattela <i>et al.</i> , "Bcl-x and Bcl-2 inhibit TNF and Fas-induced apoptosis and activation of phospholipase A2 in breast carcinoma cells," <i>Oncogene</i> , 10:2297-2305, 1995.
	C83	Jawhari <i>et al.</i> , "Up-regulated cytoplasmic expression, with reduced membranous distribution, of the src substrate p120(ctn) in gastric carcinoma," <i>J. Pathol.</i> 189:180-5, 1999.
	C84	Jen <i>et al.</i> , "Suppression of gene expression by targeted disruption of messenger RNA: available options and current strategies," <i>Stem Cells</i> , 18:307-319, 2000.
	C85	Jin <i>et al.</i> , "CIAP1 and the serine protease HTRA2 are involved in a novel p53-dependent apoptosis pathway in mammals," <i>Genes Dev.</i> , 17:359-67, 2003.
	C86	Kahn <i>et al.</i> , "Nonpeptide Mimetics of beta-Turns: A Facile Oxidative Intramolecular Cycloaddition of an Azodicarbonyl System," <i>J. Amer. Chem. Soc.</i> , 110:1638-9, 1988.
	C87	Kahn, "The design and synthesis of mimetics of peptide beta-turns," <i>J. Molec. Recognition</i> , 1:75-9, 1988.
	C88	Kalofonos <i>et al.</i> , "Kinetics, quantitative analysis and radioimmunolocalisation using indium-111-HMFG1 monoclonal antibody in patients with breast cancer," <i>Cr. J. Cancer</i> , 59:939-942, 1989.
	C89	Kalofonos <i>et al.</i> , "Radioimmunoschintigraphy in patients with ovarian cancer," <i>Acta Oncologica</i> , 38:629-634, 1999.
	C90	Karvinen <i>et al.</i> , "Homogeneous time-resolved fluorescence quenching assay (LANCE) for caspase-3," <i>J. Biomol. Screen.</i> , 7:223-31, 2002.
	C91	Kataoka <i>et al.</i> , "FLIP prevents apoptosis induced by death receptors but not by perforin/granzyme B, chemotherapeutic drugs, and gamma irradiation," <i>J. Immunol.</i> , 161:3936-3942, 1998.
	C92	Kayagaki <i>et al.</i> , "Metalloproteinase-mediated release of human Fas ligand," <i>J. Exp. Med.</i> , 182:1777-1783, 1995.
	C93	Kemp and Stites, "A convenient preparation of derivatives of 3(s)-amino-109(r)-carboxy-1,6-diazacyclodeca-2,7-dione the dilactam of L-alph,gamma-diaminobutyric acid and d-glutamic acid: a beta-turn template," <i>Tet. Lett.</i> , 29:5057-60, 1988.

25794698.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No.: DFC1:006US	Serial No.: 10/598,295
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)			
U.S. Patent Documents <i>See Page 1-2</i>		Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 3-19</i>

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C94	Kennerdell <i>et al.</i> , "Heritable gene silencing in <i>Drosophila</i> using double-stranded RNA," <i>Nature Biotechnology</i> , 17:896-898, 2000.
	C95	Kharbanda <i>et al.</i> , "Nuclear signaling induced by ionizing radiation involves colocalization of the activated p56/p53lyn tyrosine kinase with p34cdc2," <i>Cancer Res.</i> , 56:3617-3621, 1996.
	C96	Kim <i>et al.</i> , "Cholestryl oligoarginine delivering vascular endothelial growth factor siRNA effectively inhibits tumor growth in colon adenocarcinoma," <i>Molecular Therapy</i> , 14:343-350, 2006.
	C97	Kischkel <i>et al.</i> , "Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signalling complex (DISC) with the receptor," <i>EMBO J.</i> , 14:5579-5588, 1995.
	C98	Kluck <i>et al.</i> , "The Release of Cytochrome c from Mitochondria: A Primary Site for BCL-2 Regulation of Apoptosis," <i>Science</i> , 275:1132-1136, 1997.
	C99	Kondo <i>et al.</i> , "Decreased MUC1 expression induces E-Cadherin-mediated cell adhesion of breast cancer cell lines," <i>Cancer Research</i> , 58:2014-2019, 1998.
	C100	Kroemer and Reed, "Mitochondrial control of cell death," <i>Nat. Med.</i> , 6:513-519, 2000.
	C101	Kufe <i>et al.</i> , "Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors," <i>Hybridoma</i> , 3:223-232, 1984.
	C102	Kumar <i>et al.</i> , "Abrogation of the cell death response to oxidative stress by the c-Abl tyrosine kinase inhibitor ST1571," <i>Mol. Pharmacol.</i> , 63:276-282, 2003.
	C103	Kuppuswamy <i>et al.</i> , "Multiple functional domains of Tat, the trans-activator of HIV-1, defined by mutational analysis," <i>Nucl. Acids Res.</i> , 17:3551-61, 1989.
	C104	LaVallee <i>et al.</i> , "2-Methoxyestradiol up-regulates death receptor 5 and induces apoptosis through activation of the extrinsic pathway," <i>Cancer Research</i> , 63:468-475, 2003.
	C105	LeBlanc <i>et al.</i> , "Tumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax," <i>Nat. Med.</i> , 8:274-281, 2002.
	C106	Lewis <i>et al.</i> , "Efficient delivery of siRNA for inhibition of gene expression in postnatal mice," <i>Nature Genetics</i> , 32:107-108, 2002.
	C107	Li and Kufe, "The human DF3/MUC1 carcinoma-associated antigen signals nuclear localization of the catenin p120 ^{ctn} ," <i>Biochem. Biophys. Res. Commun.</i> , 281:440-443, 2001.

25794698.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No.: DFCL:006US	Serial No.: 10/598,295
List of Patents and Publications for Applicant's		
INFORMATION DISCLOSURE STATEMENT		
(Use several sheets if necessary)		
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 3-19</i>

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C108	Li <i>et al.</i> , "Cleavage of BID by Caspase 8 Mediates the Mitochondrial Damage in the FAS Pathway of Apoptosis," <i>Cell</i> , 94:491-501, 1998.
	C109	Li <i>et al.</i> , "Cytochrome c and dATP-Dependent Formation of Apaf-1/Caspase-9 Complex initiates and Apoptotic Protease Cascade," <i>Cell</i> , 91:479-489, 1997.
	C110	Li <i>et al.</i> , "DF3/MUC1 signaling in multiple myeloma cells is regulated by interleukin-7," <i>Cancer Biol. Ther.</i> , 2:187-193, 2003.
	C111	Li <i>et al.</i> , "Heregulin targets gamma-catenin to the nucleolus by a mechanism dependent on the DF3/MUC1 oncoprotein," <i>Mol. Cancer Res.</i> , 1:765-775, 2003.
	C112	Li <i>et al.</i> , "Human DF3/MUC1 carcinoma-associated protein functions as an oncogene," <i>Oncogene</i> , 22:6107-6110, 2003.
	C113	Li <i>et al.</i> , "Interaction of glycogen synthase kinase 3β with the DF3/MUC1 carcinoma-associated antigen and β-catenin," <i>Mol. Cell. Biol.</i> , 18:7216-7224, 1998.
	C114	Li <i>et al.</i> , "The c-Src tyrosine kinase regulates signaling of the human DF3/MUC1 carcinoma-associated antigen with GSK3β and β-catenin," <i>J. Biol. Chem.</i> , 276:6061-6064, 2001.
	C115	Li <i>et al.</i> , "The EGF receptor regulates interaction of the human DF3/MUC1 carcinoma antigen with c-SRC and β-catenin," <i>JBC Papers in Press</i> , manuscript C100359200, August 1, 2001.
	C116	Li <i>et al.</i> , "The epidermal growth factor receptor regulates interaction of the human DF3/MUC1 carcinoma antigen with c-Src and beta-catenin," <i>J. Biol. Chem.</i> , 276:35236-42, 2001.
	C117	Li <i>et al.</i> , "Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque," <i>Nature Med.</i> , 11:944-951, 2005.
	C118	Ligtenberg <i>et al.</i> , "Cell associated episialin is a complex containing two proteins derived from a common precurso," <i>J. Biol. Chem.</i> , 267:6171-6177, 1992.
	C119	Ligtenberg <i>et al.</i> , "Suppression of Cellular Aggregation by High Levels of Episialin," <i>Cancer Res.</i> , 52:2318-2324, 1992.
	C120	Lin <i>et al.</i> , "Inhibition of nuclear translocation of transcription factor NF-κappa B by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence," <i>J. Biol. Chem.</i> , 270:14255-8, 1995.
	C121	Liu <i>et al.</i> , "Identification of a functionally important sequence in the cytoplasmic tail of integrin beta 3 by using cell-permeable peptide analogs," <i>Proc. Natl Acad. Sci. U.S.A.</i> , 93:11819-24, 1996.

25794698.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No.: DFCI:006US	Serial No.: 10/598,295
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT <small>(Use several sheets if necessary)</small>			
U.S. Patent Documents <i>See Page 1-2</i>		Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 3-19</i>

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C122	Liu <i>et al.</i> , "Induction of Apoptotic Program in Cell-Free Extracts: Requirement of dATP and Cytochrome c," <i>Cell</i> , 86:147-157, 1996.
	C123	Luo <i>et al.</i> , "An efficient intrathecal delivery of small interfering RNA to the spinal cord and peripheral neurons," <i>Molecular Pain</i> , 1:29, 2005.
	C124	Luo <i>et al.</i> , "Bid, A Bcl2 Interacting Protein, Mediates Cytochrome c Release from Mitochondria in Response to Activation of Cell Surface Death Receptors," <i>Cell</i> , 94:481-490, 1998.
	C125	Makimura <i>et al.</i> , "Reducing hypothalamic AGRP by RNA interference increases metabolic rate and decreases body weight without influencing food intake," <i>BMC Neuroscience</i> , 3:18, 2002.
	C126	Maraveydas <i>et al.</i> , "Pharmacokinetics and toxicity of an Yttrium-90-CITC-DTPA-HMFG1 radioimmunoconjugate for intraperitoneal radioimmunotherapy of ovarian cancer," <i>Cancer</i> , 73:1067-1075, 1994.
	C127	Maraveydas <i>et al.</i> , "Pharmacokinetics, biodistribution, and dosimetry of specific and control radiolabeled monoclonal antibodies in patients with primary head and neck squamous cell carcinoma," <i>Cancer Research</i> , 55:1060-1069, 1995.
	C128	Mariani <i>et al.</i> , "Regulation of cell surface APO-1/Fas (CD95) ligand expression by metalloproteases," <i>Eur. J. Immunol.</i> , 25:2303-2307, 1995.
	C129	Marsters <i>et al.</i> , "A novel receptor for Apo2L/TRAIL contains a truncated death domain," <i>Curr. Biol.</i> , 7:1003-1006, 1997.
	C130	Martinez <i>et al.</i> , "Single-stranded antisense siRNAs guide target RNA cleavage in RNAi," <i>Cell</i> , 110:563-574, 2002.
	C131	Martins, "The serine protease Omi/HtrA2: a second mammalian protein with a Reaper-like function," <i>Cell Death Diff.</i> , 9:699-701, 2002.
	C132	McGuckin <i>et al.</i> , "Prognostic significance of MUC1 epithelial mucin expression in breast cancer," <i>Human Pathology</i> , 26:432-439, 1995.
	C133	Mi <i>et al.</i> , "Characterization of a class of cationic peptides able to facilitate efficient protein transduction in vitro and in vivo," <i>Mol. Ther.</i> , 2:339-47, 2000.
	C134	Milik <i>et al.</i> , "Lung lymphocyte elimination by apoptosis in the murine response to intratracheal particulate antigen," <i>J. Clin. Invest.</i> , 99:1082-1091, 1997.

25794698.1

EXAMINER:**DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No.: DFCI:006US	Serial No.: 10/598,295
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT <small>(Use several sheets if necessary)</small>			
U.S. Patent Documents <i>See Page 1-2</i>		Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 3-19</i>

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C135	Minakuchi <i>et al.</i> , "Atelocollagen-mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo," <i>Nucleic Acids Research</i> , 32:e109, 2004.
	C136	Molenaar <i>et al.</i> , "XTCf-3 transcription factor mediates beta-catenin-induced axis formation in <i>Xenopus</i> embryos," <i>Cell</i> , 86:391-9, 1996.
	C137	Morris <i>et al.</i> , "A new peptide vector for efficient delivery of oligonucleotides into mammalian cells," <i>Nucleic Acid Res.</i> , 25:2730-6, 1997.
	C138	Muzio <i>et al.</i> , "FLICE, A Novel FADD-Homologous ICE/CED-3-like Protease, Is Recruited to the CD95 (fas/APO-1) Death-Inducing Signaling Complex," <i>Cell</i> , 85:817-827, 1996.
	C139	Nagai and Sato, "Synthesis of a bicyclic dipeptide with the shape of beta-turn central part," <i>Tet. Lett.</i> , 26:647-50, 1985.
	C140	Nagata, "Apoptosis by Death Factor," <i>Cell</i> , 88:355-365, 1997.
	C141	Nakamura <i>et al.</i> , "RNA interference targeting transforming growth factor-beta type II receptor suppresses ocular inflammation and fibrosis," <i>Molecular Vision</i> , 10:703-711, 2004.
	C142	Nakashima <i>et al.</i> , "Inhibition of angiogenesis by a new isocoumarin, NM-3," <i>J. Antibiotics</i> , 52:426-428, 1999.
	C143	Nicholson <i>et al.</i> , "Radioimmunotherapy after chemotherapy compared to chemotherapy alone in the treatment of advanced ovarian cancer: a matched analysis," <i>Oncology Reports</i> 5:223-226, 1998.
	C144	Niethammer <i>et al.</i> , "CRIPt, a novel postsynaptic protein that binds to the third PDZ domain of PSD-95/SAP90," <i>Neuron</i> , 20:693-707, 1998.
	C145	Niu <i>et al.</i> , "Inhibition of HPV 16 E6 oncogene expression by RNA interference in vitro and in vivo," <i>Int. J. Gynecol. Cancer</i> , 16:743-751, 2006.
	C146	Novak and Dedhar, "Signaling through beta-catenin and Lef/Tcf," <i>Cell Mol. Life Sci.</i> , 52:3-37, 1999.
	C147	Obermair <i>et al.</i> , "Expression of MUC1 splice variants in benign and malignant ovarian tumours," <i>Int. J. Cancer</i> , 100:166-171, 2002.
	C148	Oehlke <i>et al.</i> , "Cellular uptake of an alpha-helical amphipathic model peptide with the potential to deliver polar compounds into the cell interior non-endocytically," <i>Biochim. Biophys. Acta</i> , 1414: 127-39, 1998.

25794698.1

EXAMINER:**DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No.: DFCI:006US	Serial No.: 10/598,295
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT <small>(Use several sheets if necessary)</small>			
U.S. Patent Documents <i>See Page 1-2</i>		Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 3-19</i>

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C149	Okazaki <i>et al.</i> , "Downregulation of gastric mucin gene expression and its biosynthesis by dexamethasone in the human," <i>J. Clin. Gastroenterol.</i> , 27(suppl. 1):S91-S92, 1998.
	C150	Opalinska <i>et al.</i> , "Nucleic-acid therapeutics: basic principles and recent applications," <i>Nature Reviews Drug Discovery</i> , 1:503-514, 2002.
	C151	Padrón <i>et al.</i> , "Selective cell kill of the combination of gemcitabine and cisplatin in multilayered postconfluent tumor cell cultures," <i>Anti-Cancer Drugs</i> , 10:445-452, 1999.
	C152	Palliser <i>et al.</i> , "An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection," <i>Nature</i> , 439:89-94, 2006.
	C153	Pan <i>et al.</i> , "An Antagonist Decoy Receptor and a Death Domain-Containing Receptor for TRAIL," <i>Science</i> , 277:815-818, 1997.
	C154	Pan <i>et al.</i> , "The Receptor for the Cytotoxic Ligand TRAIL," <i>Science</i> , 276:111-113, 1997.
	C155	Parrish <i>et al.</i> , "Functional anatomy of a dsRNA trigger: differential requirement for the two trigger strands in RNA interference," <i>Molecular Cell</i> , 8:1077-1087, 2000.
	C156	Paszkiewicz-Gadek <i>et al.</i> , "Biosynthesis of MUC1 mucin in human endometrial adenocarcinoma is modulated by estradiol and tamoxifen," <i>Gynecol. Endocrinol.</i> , 17:37-44, 2003.
	C157	Pavlovic <i>et al.</i> , "Targeting of non-small cell lung cancer using HMFG1- ^{99m} TC monoclonal antibodies," <i>Med Pregl.</i> , 46 Suppl 1:26-28, 1993
	C158	Perey <i>et al.</i> , "Tumor selective reactivity of a monoclonal antibody prepared against a recombinant peptide derived from the DF3 human breast carcinoma-associated antigen," <i>Cancer Research</i> , 52:2563-2568, 1992.
	C159	Perez <i>et al.</i> , "Antennapedia homeobox as a signal for the cellular internalization and nuclear addressing of a small exogenous peptide," <i>J. Cell. Sci.</i> , 102:717-22, 1992.
	C160	Pescarolo <i>et al.</i> , "A retro-inverso peptide homologous to helix 1 of c-Myc is a potent and specific inhibitor of proliferation in different cellular systems," <i>FASEB J.</i> , 15:31-3, 2001.
	C161	Pitti <i>et al.</i> , "Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family," <i>J. Biol. Chem.</i> , 271:12687-12690, 1996.
	C162	Pooga <i>et al.</i> , "Cell penetrating PNA constructs regulate galanin receptor levels and modify pain transmission in vivo," <i>Nature Biotech.</i> , 16:857-61, 1998.

25794698.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No.: DFCI:006US	Serial No.: 10/598,295
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT <small>(Use several sheets if necessary)</small>			
U.S. Patent Documents <i>See Page 1-2</i>		Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 3-19</i>

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C163	Porowska <i>et al.</i> , "MUC1 expression in human breast cancer cells is altered by the factors affecting cell proliferation," <i>Neoplasma</i> , 49:104-109, 2002.
	C164	Price <i>et al.</i> , "Summary report on the ISOBOIM TD-4 workshop: analysis of 56 monoclonal antibodies against the MUC1 mucin," San Diego, California, November 17-23, 1996, <i>Tumor Biol.</i> , 19:sup. 1:1-20, 1998.
	C165	Reddish <i>et al.</i> , "Pre-immunotherapy serum CA27.29 (MUC-1) mucin level and CD69+ lymphocytes correlate with effects of Theratope sialyl-Tn-KLH cancer vaccine in active specific immunotherapy," <i>Cancer Immunol. Immunother.</i> , 42:303-9, 1996.
	C166	Reich <i>et al.</i> , "Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model," <i>Molecular Vision</i> , 9:210-216, 2003.
	C167	Ren <i>et al.</i> , "Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents," <i>Cancer Cell</i> , 5:163-175, 2004.
	C168	Ren <i>et al.</i> , "Protein kinase C delta regulates function of the DF3/MUC1 carcinoma antigen in beta-catenin signaling," <i>J. Biol. Chem.</i> , 277:17616-17622, 2002.
	C169	Reynolds <i>et al.</i> , "Identification of a new catenin: the tyrosine kinase substrate p120cas associates with E-cadherin complexes," <i>Mol. Cell. Biol.</i> , 14:8333-42, 1994.
	C170	Reynolds <i>et al.</i> , "Transformation-specific tyrosine phosphorylation of a novel cellular protein in chicken cells expressing oncogenic variants of the avian cellular src gene," <i>Mol. Cell. Biol.</i> , 9:629-38, 1989.
	C171	Rondinone, "Therapeutic potential of mai in metabolic diseases," <i>BioTechniques</i> , 40:S31-S36, 2006.
	C172	Rousselle <i>et al.</i> , "New advances in the transport of doxorubicin through the blood-brain barrier by a peptide vector-mediated strategy," <i>Mol. Pharmacol.</i> , 57:679-86, 2000.
	C173	Ruben <i>et al.</i> , "Structural and functional characterization of human immunodeficiency virus tat protein," <i>J. Virol.</i> , 63(1):1-8, 1989.
	C174	Sato <i>et al.</i> , "FAP-1: A Protein Tyrosine Phosphatase That Associates with Fas," <i>Science</i> , 268:411-415, 1995.
	C175	Scaffidi <i>et al.</i> , "Differential Modulation of Apoptosis Sensitivity in CD95 Type I and Type II Cells," <i>J. Biol. Chem.</i> , 274:22532-22538, 1999.

25794698.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No.: DFCI:006US	Serial No.: 10/598,295
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Donald W. KUFE Surender KHARBANDA	
		Filing Date: April 5, 2007	Group: 1635
U.S. Patent Documents <i>See Page 1-2</i>		Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 3-19</i>

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C176	Schiffelers <i>et al.</i> , "Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle," <i>Nucleic Acids Research</i> , 32:e149, 2004.
	C177	Schneider <i>et al.</i> , "Mutagenesis and selection of PDZ domains that bind new protein targets," <i>Nat Biotech</i> , 17:170-5, 1998.
	C178	Schultz <i>et al.</i> , "Specific interactions between the syntrophin PDZ domain and voltage-gated sodium channels," <i>Nat. Struct. Biol.</i> , 5:19-24, 1998.
	C179	Schumacher <i>et al.</i> , "Immunoscintigraphy with positron emission tomography: Gallium-68 chelate imaging of breast cancer pretargeted with bispecific anti-MUC1/anti-Ga chelate antibodies," <i>Cancer Research</i> , 61:3712-3717, 2001.
	C180	Shen <i>et al.</i> , "Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1," <i>Gene Therapy</i> , 13:225-234, 2006.
	C181	Shimazui <i>et al.</i> , "Prognostic value of cadherin-associated molecules (alpha-, beta-, and gamma-catenins and p120cas) in bladder tumors," <i>Cancer Res.</i> , 56:4154-8, 1996.
	C182	Siddiqui <i>et al.</i> , "Isolation and sequencing of a cDNA coding for the human DF3 breast carcinoma-associated antigen," <i>Proc. Natl. Acad. Sci. USA</i> , 85:2320-2323, 1988.
	C183	Smith and Waterman, "Comparison of Biosequences," <i>Adv. Appl. Math.</i> , 2:482-9, 1981.
	C184	Smith, "Design, Synthesis, and Crystal Structure of a Pyrrolin-Based Peptidomimetic Possessing the Conformation of a beta-Strand: Potential Application to the Design of Novel Inhibitors of Proteolytic Enzymes," <i>J. Amer. Chem. Soc.</i> , 114:10672-4, 1992.
	C185	Snyder <i>et al.</i> , "Treatment of Terminal Peritoneal Carcinomatosis by a Transducible p53-Activating peptide," <i>PLoS Biology</i> , 2:186-93, 2004.
	C186	Songyang <i>et al.</i> , "Recognition of unique carboxyl-terminal motifs by distinct PDZ domains," <i>Science</i> , 275:73-7, 1997.
	C187	Soomets <i>et al.</i> , "Deletion analogues of transportan," <i>Biochim. Biophys. Acta</i> , 1467:165-176, 2000.
	C188	Soutschek <i>et al.</i> , "Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs," <i>Nature</i> , 432:173-178, 2004.
	C189	Spatola, "A Peptide Backbone Modifications," In: <i>Chemistry and Biochemistry of Amino Acids, Peptides and Proteins</i> , 7:267-357, Marcell Dekker, NY, 1983.

25794698.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No.: DFCI:006US	Serial No.: 10/598,295
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Donald W. KUFE Surender KHARBANDA	
U.S. Patent Documents <i>See Page 1-2</i>		Foreign Patent Documents <i>See Page 2</i>	Filing Date: April 5, 2007 Group: 1635
		Other Art <i>See Page 3-19</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C190	Srinivasan <i>et al.</i> , "Bcl-xL functions downstream of caspase-8 to inhibit Fas- and tumor necrosis factor receptor 1-induced apoptosis of MCF7 breast carcinoma cells," <i>J. Biol. Chem.</i> , 273:4523-4529, 1998.
	C191	Srinivasula <i>et al.</i> , "Autoactivation of procaspase-9 by Apaf-1-mediated oligomerization," <i>Mol. Cell.</i> , 1:949-957, 1998.
	C192	Stennicke <i>et al.</i> , "Pro-caspase-3 is a major physiologic target of caspase-8," <i>J. Biol. Chem.</i> , 273:27084-27090, 1998.
	C193	Strous and Decker, "Mucin-Type Glycoproteins," <i>Crit. Rev. Biochem., Mol. Biol.</i> , 27:57-92, 1992.
	C194	Subbarao <i>et al.</i> , "pH-dependent bilayer destabilization by an amphipathic peptide," <i>Biochemistry</i> , 26:2964-2972, 1987.
	C195	Takei <i>et al.</i> , "A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics," <i>Cancer Research</i> , 64:3365-3370, 2004.
	C196	Takeichi, "Cadherins: a molecular family important in selective cell-cell adhesion," <i>Annu. Rev. Biochem.</i> , 59:237-52, 1990.
	C197	Taylor <i>et al.</i> , "Antisense oligonucleotides: a systematic high-throughput approach to target validation and gene function determination," <i>Drug Discovery Today</i> , 4:562-567, 1999.
	C198	Thakker <i>et al.</i> , "siRNA-mediated knockdown of the serotonin transporter in the adult mouse brain," <i>Molecular Psychiatry</i> , 10:782-789, 2005.
	C199	Timmer <i>et al.</i> , "Fas receptor-mediated apoptosis: a clinical application?" <i>J. Pathol.</i> , 196:125-134, 2002.
	C200	Tondini <i>et al.</i> , "Evaluation of monoclonal antibody DF3 conjugated with ricin as a specific immunotoxin for <i>in Vitro</i> purging of human bone marrow," <i>Cancer Research</i> , 50:1170-1175, 1990.
	C201	Topp <i>et al.</i> , "MUC-1 specific T-cells are present in multiple myeloma patients at high frequency after allogeneic transplantation but may not mediate the graft versus myeloma effect," <i>Blood</i> , 100: page Abstract No. 5191, 2002.
	C202	Torchilin and Levchenko, "TAT-liposomes: a novel intracellular drug carrier," <i>Curr. Protein Pept. Sci.</i> , 4:133-40, 2003.

25794698.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No.: DFCI:006US	Serial No.: 10/598,295
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT <small>(Use several sheets if necessary)</small>			
U.S. Patent Documents <i>See Page 1-2</i>		Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 3-19</i>

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C203	Tseng <i>et al.</i> , "Translocation of liposomes into cancer cells by cell-penetrating peptides penetratin and tat: a kinetic and efficacy study," <i>Mol. Pharmacol.</i> , 62:864-72, 2002.
	C204	Urban-Klein <i>et al.</i> , "RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA <i>in vivo</i> ," <i>Gene Therapy</i> , 12:461-466, 2005.
	C205	van Hof <i>et al.</i> , "Biodistribution of 111Indium-labeled engineered human antibody CTMO1 in ovarian cancer patients: influence of protein dose," <i>Cancer Research</i> , 56:5179-5185, 1996.
	C206	Verhagen <i>et al.</i> , "Identification of DIABLO, a Mammalian Protein that Promotes Apoptosis by Binding to and Antagonizing IAP Proteins," <i>Cell</i> , 102:43-53, 2000.
	C207	Vermeer <i>et al.</i> , "Segregation of receptor and ligand regulates activation of epithelial growth factor receptor," <i>Nature</i> , 422:322-326, 2003.
	C208	Vives <i>et al.</i> , "A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus," <i>J. Biol. Chem.</i> , 272:16010-7, 1997.
	C209	Walczak <i>et al.</i> , "TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL," <i>EMBO J.</i> , 16:5386-5397, 1997.
	C210	Walczak <i>et al.</i> , "Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand <i>in vivo</i> ," <i>Nat. Med.</i> , 5:157-163, 1999.
	C211	Walsh <i>et al.</i> , "Heterogeneity of MUC1 expression by human breast carcinoma cell lines <i>in vivo</i> and <i>in vitro</i> ," <i>Breast Cancer Research and Treatment</i> , 58:255-266, 2000.
	C212	Wang and El-Deiry, "TRAIL and apoptosis induction by TNF-family death receptors," <i>Oncogene</i> , 24:8628-8633, 2003.
	C213	Wei <i>et al.</i> , "MUC1 oncoprotein stabilizes and activates estrogen receptor α ," <i>Molecular Cell</i> , 21:295-305, 2006.
	C214	Wender <i>et al.</i> , "The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters," <i>Proc. Natl. Acad. Sci., U.S.A.</i> , 97:13003-8, 2000.
	C215	Williams <i>et al.</i> , "Selective inhibition of growth factor-stimulated mitogenesis by a cell-permeable Grb2-binding peptide," <i>J. Biol. Chem.</i> , 272:22349-54, 1997.

25794698.1

EXAMINER:**DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No.: DFCL006US	Serial No.: 10/598,295
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)			
U.S. Patent Documents <i>See Page 1-2</i>		Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 3-19</i>

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C216	Wreschner <i>et al.</i> , "Does a novel form of the breast cancer marker protein MUC1, act as receptor molecule that modulates signal transduction," In: <i>Antigen and Antibody Molecular Engineering in Breast Cancer Diagnosis and Treatment</i> , Ed. Ceriani Plenum Press, New York, pp. 17-26, 1994.
	C217	Xia <i>et al.</i> , "siRNA-mediated gene silencing in vitro and invivo," <i>Nature Biotechnology</i> , 20:1006-1010, 2002.
	C218	Yamamoto <i>et al.</i> , "Interaction of the DF3/MUC1 breast carcinoma-associated antigen and beta-catenin in cell adhesion," <i>J. Biol. Chem.</i> , 272:12492-4, 1997.
	C219	Yang <i>et al.</i> , "Prevention of Apoptosis by Bcl-2: Release of Cytochrome c from Mitochondria Blocked," <i>Science</i> , 275:1129-1132, 1997.
	C220	Zimmerman <i>et al.</i> , "RNAi-mediated gene silencing in non-human primates," <i>Nature</i> , 441:111-114, 2006.
	C221	Zrihan-Licht <i>et al.</i> , "Characterization and molecular cloning of a novel MUC1 protein, devoid of tandem repeats, expressed in human breast cancer tissue," <i>Eur. J. Biochem.</i> , 224:787-795, 1994.
	C222	Zrihan-Licht <i>et al.</i> , "Tyrosine phosphorylation of the MUC1 breast cancer membrane proteins: cytokine receptor-like molecules," <i>FEBS Lett.</i> , 356:130-136, 1994.

25794698.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609, DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.